You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

Details for Patent: RE46617


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent RE46617 protect, and when does it expire?

Patent RE46617 protects BAXDELA and is included in two NDAs.

This patent has forty-three patent family members in twenty-six countries.

Summary for Patent: RE46617
Title:Process for making quinolone compounds
Abstract: The present invention relates to the field of synthesizing anti-infective compounds. More particularly, the invention relates to synthesizing a family of quinolone compounds useful as anti-infective agents. The invention includes a process for preparing a quinolone compound wherein less than about 0.40% of dimeric impurity of the quinolone is produced.
Inventor(s): Hanselmann; Roger (Branford, CT), Reeve; Maxwell M. (Guilford, CT), Johnson; Graham (Madison, CT)
Assignee: MELINTA THERAPEUTICS, INC. (New Haven, CT)
Application Number:14/743,365
Patent Claim Types:
see list of patent claims
Composition; Compound; Process;
Patent landscape, scope, and claims:

Understanding the Scope and Claims of U.S. Patents: A Detailed Analysis

Introduction

Patents are a cornerstone of innovation, providing inventors and companies with exclusive rights to their inventions. The U.S. patent system, governed by the U.S. Patent and Trademark Office (USPTO), is complex and multifaceted. This article will delve into the scope and claims of U.S. patents, using the context of U.S. Patent RE46617 as a reference point, although specific details of this patent are not provided here.

The Patent Trial and Appeal Board (PTAB) and Inter Partes Review

The Leahy-Smith America Invents Act (AIA) of 2011 significantly altered the U.S. patent landscape by establishing the Patent Trial and Appeal Board (PTAB) within the USPTO. PTAB is empowered to conduct administrative challenges to the validity of patents, including Inter Partes Review (IPR) and Post-Grant Review (PGR). These proceedings allow anyone to challenge the validity of a patent, potentially leading to the cancellation of patent claims if PTAB determines they should not have been issued[1].

Patentability Requirements

For a patent to be granted, it must meet several key requirements:

Eligible Subject Matter Requirement

The Patent Act allows patents on new and useful "process, machine, manufacture, or composition of matter, or improvement thereof." However, laws of nature, natural phenomena, and abstract ideas are not patentable. The Supreme Court's Alice/Mayo test is used to determine if a patent claim is directed to ineligible subject matter and whether it contains an "inventive concept" that transforms the nature of the claim into a patent-eligible application[1].

Novelty Requirement

The claimed invention must be novel, meaning it must not have been patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention[1].

Nonobviousness Requirement

Even if an invention is novel, it must also be nonobvious. This means that the invention must be significantly different from what was already known in the prior art, and it cannot be obvious to a person of ordinary skill in the relevant field[1].

Patent Claims and Scope

Patent claims define the scope of the invention and are crucial in determining what is protected by the patent. The USPTO's Patent Claims Research Dataset provides detailed information on claims from U.S. patents granted between 1976 and 2014 and patent applications published between 2001 and 2014. This dataset helps in understanding the dependency relationships between claims and the overall scope of the patent[3].

The Value of a Patent

The value of a patent can be substantial and is often determined using three main valuation methods: cost, income, and market.

Cost Approach

This method considers the replacement cost or the cost incurred in developing the patent. However, since patents are unique and cannot be replicated, this method is less commonly used[5].

Income Approach

This approach calculates the present value of the future benefits provided by the patent, such as income or savings. It is a more relevant method for patents that generate significant revenue[5].

Market Approach

This method determines the value based on what a willing buyer would pay for a similar patent. It involves analyzing sales and asking price data for comparable patents. For example, the mean price per document for a set of 43,000 documents was $483,924, with prices ranging from $18,000 to $1,000,000 per family[5].

Small Claims Patent Court

There has been ongoing discussion about the need for a small claims patent court to address the high costs and complexity associated with patent litigation. The Administrative Conference of the United States (ACUS) conducted a study to explore the feasibility and potential structure of such a court, engaging with a wide range of stakeholders and experts in the field[2].

Patent Landscape and Trends

The U.S. patent landscape is dynamic, with trends and statistics providing insights into the innovation ecosystem. For instance, data from the National Science Foundation (NSF) shows county-level patent activity, highlighting areas of high innovation and the distribution of patents across different technical fields[4].

Key Takeaways

  • PTAB and IPR: The PTAB plays a critical role in challenging patent validity through IPR and PGR, offering a faster and less expensive alternative to judicial proceedings.
  • Patentability Requirements: Patents must meet eligibility, novelty, and nonobviousness requirements to be granted.
  • Patent Claims: Claims define the scope of the invention and are essential in determining patent protection.
  • Valuation Methods: The value of a patent can be determined using cost, income, and market approaches.
  • Small Claims Court: There is a growing interest in establishing a small claims patent court to make patent litigation more accessible and affordable.
  • Patent Trends: Understanding patent trends and statistics can provide valuable insights into innovation patterns and the patent landscape.

FAQs

What is the role of the Patent Trial and Appeal Board (PTAB)?

The PTAB is a tribunal within the USPTO that conducts administrative challenges to the validity of patents, including Inter Partes Review (IPR) and Post-Grant Review (PGR).

How are patent claims valued?

Patent claims can be valued using the cost, income, and market approaches. The income approach is often most relevant, as it calculates the present value of future benefits provided by the patent.

What are the key requirements for a patent to be granted?

A patent must meet the requirements of eligible subject matter, novelty, and nonobviousness to be granted.

Why is there a need for a small claims patent court?

A small claims patent court is proposed to address the high costs and complexity associated with patent litigation, making it more accessible and affordable for smaller entities.

How do trends in patent activity reflect innovation?

Trends in patent activity, such as those provided by the NSF, reflect areas of high innovation and the distribution of patents across different technical fields, offering insights into the broader innovation ecosystem.

Sources

  1. Congressional Research Service, "The Patent Trial and Appeal Board and Inter Partes Review," Updated May 28, 2024.
  2. Administrative Conference of the United States, "U.S. Patent Small Claims Court."
  3. USPTO, "Patent Claims Research Dataset."
  4. National Science Foundation, "Invention, Knowledge Transfer, and Innovation."
  5. Perpetual Motion Patents, "The Value of a Patent."

More… ↓

⤷  Subscribe


Drugs Protected by US Patent RE46617

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Melinta BAXDELA delafloxacin meglumine POWDER;INTRAVENOUS 208611-001 Jun 19, 2017 RX Yes Yes ⤷  Subscribe ⤷  Subscribe Y ⤷  Subscribe
Melinta BAXDELA delafloxacin meglumine TABLET;ORAL 208610-001 Jun 19, 2017 RX Yes Yes ⤷  Subscribe ⤷  Subscribe Y ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: RE46617

PCT Information
PCT FiledSeptember 23, 2009PCT Application Number:PCT/US2009/005276
PCT Publication Date:April 01, 2010PCT Publication Number: WO2010/036329

International Family Members for US Patent RE46617

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 3214083 ⤷  Subscribe 301091 Netherlands ⤷  Subscribe
European Patent Office 3214083 ⤷  Subscribe 122021000010 Germany ⤷  Subscribe
European Patent Office 3214083 ⤷  Subscribe 132021000000011 Italy ⤷  Subscribe
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.